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Abstract REM sleep behavior disorder (RBD) is a para-
somnia characterized by dream-enacting behavior and loss
of muscle atonia during REM sleep. Idiopathic RBD occurs
in the absence of any neurological disease or other possible
cause, is male-predominant and its clinical course is
generally chronic progressive. Secondary RBD may be
related to neurodegenerative disorders such as multiple
system atrophy, Parkinson’s disease and Lewy body
dementia. Recent long-term prospective studies have shown
that 30% to 65% of patients with idiopathic RBD will
eventually develop a neurodegenerative disorder with the
rate of emergence depending on the length of the follow-up
period. RBD may therefore be one of the earliest signs of
and/or a long-term predictor for neurodegenerative disor-
ders. Because RBD antecedes the development of these
disorders by several years or decades, its recognition may
enable the delay or prevention of neurodegenerative
disorders through the early application of neuroprotective
or disease-modifying therapies in the future.
Keywords REM sleep behavior disorder . Parkinson’s
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Abbrevations
AD Alzheimer’s disease
DLB Dementia with Lewy bodies
EEG Electroencephalography
EMG Electromyography
iRBD Idiopathic REM sleep behavior disorder
MCI Minimal cognitive impairment
MSA Multiple system atrophy
NDD Neurodegenerative disorders
NREM sleep non REM sleep
REM sleep Rapid eye movement sleep
RBD REM sleep behavior disorder
RSWA REM sleep without atonia
PD Parkinson’s disease
PDD Parkinson’s disease with dementia
Introduction
Human sleep is divided into rapid eye movement (REM)
sleep and non REM (NREM) sleep. REM sleep is
characterized by the prominent rapid eye movements and
active paralysis of all the somatic musculature except the
diaphragm to permit breathing. REM sleep behavior
disorder (RBD) is a parasomnia where the physiological
atonia during REM sleep is absent or greatly diminished
and is characterized by dream-enacting behavior associated
with nightmares. Motor behavior ranges from vocalizations
during REM sleep or simple movements to violent complex
and lasting enactment of dream content with significant
injury to the patient or a bed partner. The diagnostic criteria
for RBD according to the international classification of
sleep disorders [1] are given in Table 1 and require a
nocturnal polysomnography to document REM sleep
without atonia in the presence of dream-enacting behavior.
RBD was first described in 1987 by Schenck, Mahowald
and co-workers [2]. It is a male-predominant disorder and
usually emerges after the age of 50 years but has also been
observed in younger patients [1]. At present, its prevalence
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is unknown but estimates range from 0.3 and 0.8% [1]. The
onset of RBD can be gradual or rapid but the course is
generally chronic and progressive [2]. Complications can
include injuries to the patient or a bed partner, which can be
life-threatening [3]. Clonazepam, usually in doses of 0.25
to 0.5 mg/night, is efficacious in the majority of patients
and is considered first-line treatment but should be used
with cautions in patients with dementia, gait disorders or
concomitant obstructive sleep apnea [4–6]. Melatonin has
also been effective in some patients with RBD [7–9].
Modifying and maintaining a safe sleeping environment
should accompany any therapeutic intervention [5].
In the idiopathic form (iRBD), RBD occurs in the
absence of any other associated neurological disorder or
possible cause. In contrast, RBD may be secondary to
neurological diseases particularly multiple system atrophy
(MSA), Parkinson’s disease (PD) and dementia with Lewy
bodies (DLB) (see below). In addition, medication use has
been recognized as a precipitating factor, specifically
antidepressants and beta-blockers [10–13].
In iRBD no evidence of neurological disease is found,
however, in many iRBD patients subclinical abnormalities
have been detected such as olfactory deficits [14–19],
cognitive dysfunction [20–22], impaired color vision [19],
and subtle cortical EEG slowing [21, 23, 24]. Other
findings include dysautonomic abnormalities [25–27],
reduced cardiac 123I-Metaiodobenzylguanidine scintigraphy
[28–31], decreased dopamine transporter imaging [32], and
increased substantia nigra echogenicity [33–35]. Follow-up
of patients with iRBD shows an increased risk for
developing neurodegenerative diseases that strongly
depends on the length of the follow-up period. Recent
evidence suggests that iRBD is an early sign of a slowly
evolving neurodegenerative disorder or a long-term predictor
of it. In the following this evidence will be summarized and
presented focusing on the prevalence and features of
RBD in neurodegenerative disorders, the emergence of
neurodegenerative disorders in long-term follow-up studies of
patients with iRBD and baseline differences between iRBD
patients who developed a neurodegenerative disease and those
who remained disease free.
REM sleep behavior disorder in neurodegenerative
diseases
RBD is frequently encountered in neurodegenerative
disorders, particularly in MSA, PD and DLB (Table 2).
The majority of patients with MSA will also have RBD
with reported prevalences of 80% to 100% [10, 36–38].
Indeed, RBD is currently considered a red flag for the
diagnosis of MSA [39]. Interestingly, the strong male
predominance encountered in the idiopathic form and in
RBD associated with PD and DLB is less evident in MSA
where only 33% to 61% of the patients are male [36, 38,
40]. Concerning the onset of RBD in relation to the
occurrence of MSA, studies with retrospective estimates
have shown that in 16% to 54% of MSA patients RBD
preceded the onset of MSA [10, 36, 38, 40, 41]. In one of
the studies RBD preceded MSA by a mean of 7 years (1 to
38 years) in 52% of the patients [10], in another [41], RBD
occurred 4 years (1 to 11 years) earlier in 36% of MSA
patients and in a third [36], RBD preceded MSA by 1 to
19 years in 44% of the patients.
The prevalence of RBD in PD lies between 30% and 41%
[42–45]. Between 65% to 75% of PD patients with RBD are
male [38, 44]. RBD occurs both in idiopathic PD and PD
secondary to genetic mutations [46] and in PD patients that
are untreated or treated with dopaminergic substances [10].
RBD is more common in the rigid-akinetic subtype of PD
than in the tremoric subtype [47, 48]. Nondemented patients
with PD and RBD are more likely to show EEG slowing
during wakefulness [49] and poorer cognitive function [50]
but RBD in PD patients has also been linked to longer
duration of PD [41, 44]. RBD in PD is not associated with
age, disease severity, depression, or sleep architecture [10].
RBD preceded PD in 18% to 25% of patients [38, 41, 48],
on average between 3 (1 to 30 years) [41] and 4 years [48].
However, in patients with Parkin mutations, RBD develops
after PD onset [46] and RBD rarely precedes PD onset in
patients with early onset PD (< 50 years) [48]. Interestingly,
it seems that in patients with iRBD who subsequently
developed PD, the onset of PD is later (~72 years) than
reported for PD patients (~62 years) [51].
The prevalence of RBD in DLB is not as well established
and available studies showed prevalences between 40% [52]
and 72% [53] again with a male predominance [10]. RBD
preceded the onset of cognitive complaints and dementia in
Table 1 Diagnostic criteria of REM sleep behavior disorder (RBD)
(taken from [1])
A REM sleep without atonia:
EMG finding of excessive amounts of sustained or
intermittent elevation of submental EMG tone or
excessive phasic submental or limb EMG twitching.
B At least one of the following:
(1) History of sleep related injurious, potentially
injurious, or disruptive behaviors
(2) Abnormal REM sleep behaviors documented
during polysomnographic monitoring
C Absence of EEG epileptiform activity during REM sleep
unless RBD can be clearly distinguished from any
concurrent REM sleep related seizure disorder.
D The sleep disorder is not better explained by another
sleep disorder, medical or neurological disorder, mental
disorder, medication use, or substance use disorder.
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the vast majority of patients (71 to 100%) [10, 41, 54, 55] and
the onset of cognitive decline followed on average 6 [54], 9
[55] or 10 years [56] later. Current consensus criteria for DLB
consider RBD as a suggestive feature of this disease [57] and
it is thought that the clinical combination of dementia and
RBD very likely indicates underlying Lewy body disease, i.e.
DLB and PD with dementia (PDD) [10].
All three disorders—MSA, PD, and DLB - are character-
ized by intraneural deposition of α-synuclein and therefore it
has been speculated that the RBD may be linked to synuclein
pathology [52]. RBD has also been observed in cases with
pure autonomic failure [58, 59]. Until recently, RBD has
been considered comparatively rare in tauopathies, however,
newer studies have reported a RBD or REM sleep without
atonia (RSWA) also in progressive supranuclear palsy (27%)
[60] and Alzheimer’s disease (7% RBD, 29% RSWA) [61].
However, RBD has not been observed in pallindopontonigral
degeneration [62]. Also, so far no case of RBD in a
patient with Pick’s disease has been reported [63]. RBD
has also been associated to autoimmune mechanisms as
REM sleep without atonia is frequently found in narco-
lepsy [64–67], another rare sleep disorder with a possible
autoimmune background. Similarly, RBD has been
observed in 5 of 6 patients with nonparaneoplastic limbic
encephalitis associated with antibodies to voltage-gated
potassium channels [68]. Interestingly, symptoms of RBD
coincided with the onset of the disorder and in 3 of the
patients immunosuppression resulted in a resolution of RBD
in parallel with the remission of the limbic syndrome [68].
In summary, at present the available evidence shows that
RBD is a common feature of synucleinopathies, especially
MSA, DLB, and PD. Nevertheless, among these disorders
RBD is distinctly more prevalent in MSA, maybe because
brainstem cell loss is widespread and severe in this disorder.
Retrospective assessment indicates that RBD frequently
precedes the onset of these disorders but this seems to be
most pronounced in DLB probably reflecting the differ-
ences in clinical course and progression in these disorders.
RBD has also been observed in tauopathies and disorders
with a neuroimmunological background, however, at the
moment the association with synucleinopathies outweighs
that with any other.
Prevalence of RBD RBD preceded onset of
neurodegenerative disorder
References
in % of patients time interval
Multiple system atrophy 80–100% 16–54% 4–7 years [10, 36–38, 40, 41]
Parkinson’s disease 30–41% 18–25% 3–4 years [38, 41–45, 48]
Dementia with
Lewy bodies
40–72% 71–100% 6–10 years [10, 41, 52–56]
Table 2 REM sleep behavior









29 patients ≥ 50 y
with iRBD
~13 y 38% (n = 11) PD ~13 y ~4 y
[8 definite PD, 2 probable
PD, 1 possible PD]
Schenck et al.
2003 [78]
~20 y 65% (n = 17 of 26) ~13 y (3–29)





~5 y (2–15 y) 45% (n = 20) ~12 y ~4 y
[7 PD, 2 PDD, 6 DLB,
1 MSA, 4 MCI]
Iranzo et al.
2008 [80]
~7 y 64% (n = 28)
[6PD, 4 PDD, 8 DLB,





~5 y 30% (n = 26) ~12 y






~11 y 65% (n = 15)
[1 PD, 3 DLB, 1 dementia,
10 reported symptoms highly
suggestive of a parkinsonian
or dementing disorder]
Table 3 New onset of
neurodegenerative disorders in
prospective follow-up studies
of patients with idiopathic REM
sleep behavior disorder
AD Alzheimer’s disease; DLB
dementia with Lewy bodies;
iRBD idiopathic REM sleep
behavior disorder; MCI minimal
cognitive impairment; MSA
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RBD as a long-term predictor for neurodegenerative
disorders
There are several case studies reporting the new onset of
neurodegenerative disorders years to decades after the
onset of RBD. This has been documented for Parkinson’s
disease [69], Lewy body disorder [70–73], multiple
system atrophy [72], and shy drager syndrome [74] and
periods of 2 to 50 years [75]. Interestingly, in two of these
cases Lewy body disease was only discovered at autopsy
[70, 76].
In systematic long-term prospective studies the percent-
age of patients with iRBD who will eventually develop a
neurodegenerative disorder ranges from 30% to 65%
strongly depending on the length of the follow-up period
(Table 3). Schenck and co-workers were the first to report
that during a follow-up time of 13 years 38% of a group of
29 male iRBD patients above 50 years of age developed PD
[77]. In a subsequent follow-up 7 years later, 65% had
developed a neurodegenerative disorder [78]. Similar
results were reported for 23 patients with iRBD of which
65% developed a neurodegenerative disorder during an
average follow-up time of 11 years [79]. In an even larger
case series of 44 consecutive iRBD patients, 45%
developed PD, DLB, MSA or minimal cognitive impairment
(MCI) after an average follow-up time of 5 years [51] and
64% after 7 years [80]. In the largest case series to date, 26
of 93 patients (30%) with iRBD developed neurodegenera-
tive disorders after an average follow-up time of 5 years [81].
In the same study [81], the authors conducted a formal
survival analysis and estimated the risk for the development
of neurodegenerative disorders as 18% for a 5 year period,
41% for a 10-year period, and 52% for a 12-year period.
Summarizing these four case series, across average follow-up
periods of 5 to 20 years 86 of 189 patients (46%) with iRBD
developed a neurodegenerative disorder. The average time
between the onset of RBD and the onset of the neurodegen-
erative disorder was 12 years and for the 76 patients with a
Table 4 Possible predictors for the development of neurodegenerative disorders in RBD: Baseline differences between iRBD patients who
developed neurodegenerative disorders and iRBD patients who remained disease free
Study Subjects Follow-up time Measured function/Main findings
Schenck et al.
1996 [77]
29 male patients ≥ 50 y with iRBD
of which 11 developed PD
~13 y Sleep, tonic and phasic chin EMG during REM sleep:
Patients with PD had increased REM sleep and periodic
leg movements at baseline.




23 iRBD of which 10 developed
MCI 10 healthy controls
2.4±1.6 y Quantitative EEG (wake, REM sleep):
Compared to healthy controls both RBD groups showed
slowing of EEG during wakefulness and REM sleep.
No significant difference between RBD with and without
MCI but trend towards greater EEG slowing during wakefulness.
Iranzo et al.
2010 [86]
43 iRBD of which 8 developed
NDDa 18 and 143 healthy controls
~2.5 y 123I-FP-CIT striatal binding, substantia nigra hyperechogenicity:
27 (63%) had reduced 123I-FP-CIT striatal binding (40%)
and/or substantia nigra hyperechogeneicity (36%).
All 8 with MCI had reduced 123I-FP-CIT uptake or substantia
nigra hyperechogenicity at baseline; 30% (8–27) of those
with abnormal imaging at baseline developed NDD).
None of the 15 iRBD patients with normal neuroimaging
developed NDD.
Postuma et al. 2010 [85] 26 iRBD with development of
NDD 26 matched iRBDD
without NDDb
~7 y Sleep, tonic and phasic chin EMG during REM sleep:
Patients with NDD had increased percentage of tonic
submental EMG activity at baseline (more severe loss
of REM atonia) and increased stage 1 sleep.




62 iRBD of which 21
developed NDDc
~5 y Olfaction, color vision testing:
Patients who developed NDD had more severe abnormalities
of olfaction and color vision at baseline
Postuma et al.
2010 [27]
42 iRBD of which 21
developed NDDd
~7 y Cardiac autonomic function:
No difference between patient groups for any
measure of cardiac autonomic function
AD Alzheimer’s disease; DLB dementia with Lewy bodies; iRBD idiopathic REM sleep behavior disorder; MCI minimal cognitive impairment;
MSA multiple system atrophy; NDD neurodegenerative disorder; PD Parkinson’s disease; PDD Parkinson’s disease dementia; y years
a 5 PD, 2 DLB, 1 MSA; b 12 PD, 1 MSA, 7 DLB, 6 dementia; c 16 PDD, 4 PD, 1 dementia; d 11 PD, 1 MSA, 5 DLB, 4AD
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definite diagnosis the new onset disorder was Parkinson’s
disease in 39 (51%), Lewy body disease in 20 (26%),
minimal cognitive impairment in 9 (12%), Alzheimer’s
disease in 5 (7%), MSA in 2 (3%) and dementia in 1
patient (Table 2).
Long-term studies in iRBD patients have shown that
over time excessive phasic and tonic muscle activity during
REM sleep increases [82], cognitive functioning declines
[83], and nigrostriatal presynaptic dopaminergic function
possible decreases [84] compatible with a general neurode-
generative process.
Possible predictors for the future development of neurode-
generative disorders in patients with iRBD have emerged from
studies that compared baseline measurement of iRBD patients
with subsequent neurodegenerative disorders to disease-free
iRBD patients (Table 4). Distinguishing characteristics in
these studies were an increase in REM sleep [77] or stage 1
sleep [85], increased tonic submental EMG activity [85],
increased striatal dopamine dysfunction or substantia
nigra hyperechogenicity [86], more severe abnormalities
of olfaction and color vision [87] and a tendency towards
more pronounced EEG slowing during wakefulness [24]
(Table 3). Interestingly, cardiac autonomic function which
differs between RBD and healthy controls [25, 26], did not
distinguish between RBD patients with subsequent neurode-
generative disorders and disease free patients, suggesting that
autonomic dysfunction in RBD may be independent from
associated PD or LBD [27]. Currently, these promising
studies await independent replication. For the future it is
hoped that the timely identification of iRBD patients who
will develop a neurodegenerative disorder provides a
window of opportunity for prevention or early treatment of
these disorders.
Summary and outlook
RBD is relatively rare sleep disorder with a male predomi-
nance that is characterized by dream-enactment and loss of
REM sleep atonia. Secondary RBD is frequently encountered
in neurodegenerative disorders and in particular in synuclei-
nopathies such as MSA, DLB, and PD. Retrospective
assessment of the onset of RBD in these disorders suggests
that RBD precedes the onset of these synucleinopathies in a
significant proportion by several years to decades. This is
confirmed by prospective long-term studies of patients with
iRBD, free of neurological disorders at the time of the
diagnosis or RBD. These studies showed that up to 60% of
patients with iRBD will subsequently develop a neurodegen-
erative disorder, most frequently PD and DLB. Again, the time
span between the onset of RBD and the onset of the subsequent
neurodegenerative disorder was around a decade with increas-
ing conversion rates across longer the follow-up periods. First
studies have also explored possible predictors for the develop-
ment of subsequent neurodegenerative diseases in iRBD
patients, but more research is needed in this area.
RBD can be seen as a long-term predictor for the
development of neurodegenerative disorders. Most likely it is
one of the earliest signs of these disorders. Indeed, for some of
these disorders such as PD, it is now apparent that the
preclinical phase can extent to 20 years or longer before the
motor manifestations [88, 89] and among the symptoms that
precede PD by 10 to 20 years are constipation, anemia, and
anxiety disorders [89]. Possible predictors for the development
of neurodegenerative disorders in patients with iRBD include
increased REM or stage 1 sleep, increased submental EMG
activity during REM sleep, striatal dopamine dysfunction and
substantia nigra hyperechogenicity, more severe abnormalities
of olfaction and color vision and EEG slowing during
wakefulness. Nocturnal polysomnograpy, imaging of dopa-
mine metabolism, transcranial sonography, olfactory and color
testing and daytime EEG may therefore by clinical tools to
identify RBD patients at an increased risk for future
neurodegenerative disorders. Because RBD precedes the
development of neurodegenerative disorders by years to
decades, its timely recognition in patients may offer a window
of opportunity where the early application of neuroprotective
or disease modifying therapies is hoped to delay or prevent
the onset of neurodegenerative disorders.
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